Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2348-2353

  Guillet, Benjamin ^a   Simon, Nicolas ^b   Sampol, Jérôme José ^a   Lorec Penet, Anne Marie ^c   Portugal, Henri ^c   Berland, Yvon ^a   Dussol, Bertrand ^a   Brunet, Philippe ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

^b Lab Biopathol Nerveuse Musculaire   (France)

^c HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Anti Xa; Anticoagulation; Enoxaparin; Haemodialysis; Nonmem; Population pharmacokinetics

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING TENDENCY; BLOOD SAMPLING; BOLUS INJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ADULT; AGED; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS;

EID: 0242320295     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg396     Document Type: Article

References (20)

1. Schrader J, Valentin R, Tonnis HJ et al. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 1985; 28: 823-829
2. Bratt G, Tornebohm E, Lockner D, Bergstrom K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost 1985; 53: 208-211
3. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114: 489S-510S
4. Schrader J, Stibbe W, Armstrong VW et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896
5. Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for hemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin. Nephrol Dial Transplant 1990; 5: 135-140
6. Janssen MJ, Deegens JK, Kapinga TH et al. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996; 49: 806-813
7. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for hemodialysis anticoagulation. Nephrol Dial Transplant 1999; 14: 2698-2703
8. Goudable C, Saivin S, Houin G, Sie P, Boneu B, Tonthat H, Suc JM. Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991; 59: 543-545
9. Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B. Pharmacokinetic of a very low molecular weight heparin in chronic renal failure. Thromb Res 1991; 63: 311-317
10. Cadroy Y, Pourrat J, Baladre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991; 63: 385-390
11. Baumelou A, Singlas E, Petitclerc T, Desmichels D, Jacobs C, Soria J. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994; 68: 202-206
12. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-775
13. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 2001; 67: 54-56
14. Ljungberg B, Blomback M, Johnsson H, Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987; 27: 31-35
15. Hainer JW, Sherrard DJ, Swan SK et al. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin Tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis 2002; 40: 531-538
16. Russo H, Simon N, Duboin MP, Urien S. Population pharmacokinetics of high-dose thiopental in patients with cerebral injuries. Clin Pharmacol Ther 1997; 62: 15-20
17. Beal SL, Sheiner LB, eds. MD NONMEM Users Guides, 1998. GloboMax LLC, Hanover
18. Sagedal S, Hartmann A, Sundstrom K, Bjornsen S, Fauchald P, Brosstad F. A single dose of dalteparin effectively prevents clotting during hemodialysis. Nephrol Dial Transplant 1999; 14: 1943-1947
19. Grau E, Siguenza F, Maduell F et al. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992; 62: 13-17
20. Shoemaker RC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42: 283-289